Radiopharmaceutical therapy (RPT) is emerging as a safe and effective targeted approach
to treating many types of cancer. In RPT, radiation is systemically or locally delivered using …

The aim of this review is to report on the current status of prostate-specific membrane
antigen (PSMA)-directed theranostics in prostate cancer (PC) patients. The value of 68 Ga …

The aim of this study was to develop a treatment protocol for 225Ac-PSMA-617 α-radiation
therapy in advanced-stage, metastatic castration-resistant prostate cancer patients with …

Prostate cancer is the most commonly diagnosed malignancy in men and the second
leading cause of cancer-related deaths in Western civilization. Although localized prostate …

Surgery is an efficient way to treat localized prostate cancer (PCa), however, it is challenging
to demarcate rapidly and accurately the tumor boundary intraoperatively, as existing tumor …

The validation of prostate specific membrane antigen (PSMA) as a molecular target in
metastatic castration-resistant prostate cancer has stimulated the development of multiple …

The prostate-specific membrane antigen (PSMA) is a molecular target whose use has
resulted in some of the most productive work toward imaging and treating prostate cancer …

The high incidence rates of prostate cancer (PCa) raise demand for improved therapeutic
strategies. Prostate tumors specifically express the prostate‐specific membrane antigen …

The treatment of metastatic castration-resistant prostate cancer (mCRPC) remains
challenging with current treatment options. The development of more effective therapies is …

Prostate specific membrane antigen (PSMA) has become a major focus point in the research
and development of prostate cancer (PCa) imaging and therapeutic strategies using …